Advaxis, Inc. , a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration has indicated the Investigational New Drug application for ADXS-NEO, a personalized neoantigen-targeted approach to cancer immunotherapy that is being developed in collaboration with Amgen , can proceed. This ground-breaking IND paves the way for bringing a new precision immunotherapy for the treatment of cancers into the clinic this year.